KDR and neoplasm: Therefore, if the numbers of adoptively transferred anti-VEGFR2 CAR-T cells are carefully escalated in the clinic, and safety mechanisms are introduced deliberately, the “On-target/Off-tumor” toxicity might be minimized [85].